Antilymphocyte globulin in cadaveric renal transplantation--a controlled trial.
In a prospective, controlled study, 40 patients receiving a cadaveric renal transplant (first grafts) were randomized into two groups. Twenty patients were given antilymphocyte globulin (Behringwerke AHLG) in a dose of 10 mg/kg body weight for a total no. of 25 times in combination with a standard regimen of prednisone and azathioprine. Graft survival and graft function were similar in the two groups both at 18 and 30 months post transplantation. No serious side effects of the ALG treatment were observed.
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005916:Globulins / Q000627:therapeutic use; D006084:Graft Rejection / Q000187:drug effects / Q000528:radiation effects; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D005916:Globulins; D007166:Immunosuppressive Agents